CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 2,239 enrolled
Drug / intervention
Aspirin +2 moredrug
Likely dose
Aspirin 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05476081
NCT05476081N/ACompleted
CompareCT.gov

A REAl-life Study on Short-term Dual Antiplatelet Treatment in Patients With Ischemic Stroke or Transient Ischemic Attack

University of L'Aquila·observational·Posted Jul 27, 2022·Updated Dec 5, 2024

In Brief

An observational study evaluating Aspirin, Clopidogrel, and 1 other intervention for Ischemic Stroke and TIA. Completed, enrolled 2,239 participants across 127 sites.

Detailed Summary

The REAl-life study on short-term Dual Antiplatelet treatment in Patients with ischemic stroke or Transient ischemic attack (READAPT) is an observational, multicenter, prospective study involving Italian centers. The study aims at evaluating effectiveness and safety of short-term (21-90 days) dual antiplatelet treatment (DAPT) in secondary prevention of mild-to-moderate ischemic stroke or high-risk TIA.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsIschemic Stroke, TIA
CountriesItaly
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedJul 27, 2022
Enrollment StartFeb 3, 2021
Primary CompletionFeb 3, 2023
Study CompletionMay 3, 2023
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 3.9 years ago

Interventions

Aspirindrug

Aspirin (100-300 mg) administered for 21-90 days in combination with another antiplatelet treatment

Clopidogreldrug

Clopidogrel (75-600 mg) administered for 21-90 days in combination with another antiplatelet treatment

Ticagrelordrug

Ticagrelor (90-180 mg) administered for 21-90 days in combination with another antiplatelet treatment